Analysis of neovasculature in uveal melanoma by targeting the TGFbeta-binding receptor endoglin: is there prognostic relevance of proliferating endothelium?

Graefe's Archive for Clinical and Experimental Ophthalmology = Albrecht Von Graefes Archiv Für Klinische Und Experimentelle Ophthalmologie
Focke ZiemssenS Grisanti

Abstract

Endoglin/CD105 is a transmembrane regulatory receptor for transforming growth factor-beta (TGF-beta) that is predominantly expressed on proliferating endothelial cells (ECs) in culture and on angiogenic blood vessels in vivo. Endoglin has been associated with angiogenesis and prognosis in several malignancies. Although microvascular structure has been characterized by a variety of different other endothelial markers so far, there is no consensus on the prognostic value of microvessel quantification in uveal melanoma due to differences in tissue pretreatment, variability in the reactivity of endothelial cell markers, blood vessel counting methods, and vasculogenic mimicry by melanoma cells expressing endothelial cell markers. The aim of this study was to investigate the expression pattern of endoglin and to evaluate whether proliferative activity of ECs determines the clinical prognosis of uveal melanoma. Paraffin sections from 35 clinicopathologically well-characterized cases of primary uveal melanomas were stained for Ki-67, von Willebrand factor (vWF) and endoglin. In 16 cases, metastatic disease led to death. The mean follow-up of the nonmetastasized cases was 10.6 (9-13) years. The immunohistological specimens were evaluate...Continue Reading

References

Jul 1, 1992·Human Pathology·S BosariM L Silverman
Nov 18, 1971·The New England Journal of Medicine·J Folkman
Aug 12, 1971·The New England Journal of Medicine·J Folkman
Aug 4, 1994·Nature·J L WranaJ Massagué
Jan 1, 1995·Breast Cancer Research and Treatment·P E Thorpe, F J Burrows
Apr 1, 1996·The Journal of Pathology·P KumarC Bernabeu
Jan 1, 1996·Breast Cancer Research and Treatment·A W GriffioenG Groenewegen
Jun 1, 1997·Melanoma Research·A M LaneE S Gragoudas
Feb 10, 2000·The American Journal of Pathology·D M McDonaldR K Jain
Dec 20, 2000·Proceedings of the National Academy of Sciences of the United States of America·Y S ChangL L Munn
Dec 12, 2001·Journal of Cutaneous Pathology·M P HoangC R Shea
Apr 16, 2002·Clinical and Experimental Dermatology·G Dawn, R M MacKie
Oct 26, 2002·Critical Reviews in Oncology/hematology·Elisabeth A SeftorMary J C Hendrix
Nov 25, 2003·APMIS : Acta Pathologica, Microbiologica, Et Immunologica Scandinavica·Helga B SalvesenLars A Akslen
Jan 20, 2004·Experimental Eye Research·Salvatore GrisantiKarl Ulrich Bartz-Schmidt
Jan 21, 2004·The Breast : Official Journal of the European Society of Mastology·M EdelH Dawkins
Jun 15, 2004·Journal of Translational Medicine·Ester Fonsatti, Michele Maio
Nov 26, 2004·APMIS : Acta Pathologica, Microbiologica, Et Immunologica Scandinavica·Stephen B Fox, Adrian L Harris
Nov 26, 2004·APMIS : Acta Pathologica, Microbiologica, Et Immunologica Scandinavica·Robert Folberg, Andrew J Maniotis

❮ Previous
Next ❯

Related Concepts

Related Feeds

Angiogenesis Inhibitors to Treat Cancer

Cancer treatments including angiogenesis inhibitors prevent tumor cells from receiving nutrients and oxygen. Here is the latest research on angiogenesis inhibitors for the treatment of cancer.

Blood Clotting Disorders

Thrombophilia includes conditions with increased tendency for excessive blood clotting. Blood clotting occurs when the body has insufficient amounts of specialized proteins that make blood clot and stop bleeding. Here is the latest research on blood clotting disorders.